GARP介导的活性TGF-β1诱导异基因造血干细胞移植后早期复发急性髓系白血病患者骨髓NK细胞功能障碍
研究通过体外实验分析异基因造血干细胞移植(allo-HSCT)后早期复发急性髓系白血病(AML)患者骨髓来源NK(BMNK)细胞功能障碍机制,发现CD4+ T细胞表面GARP过表达诱导TGF-β1活化,活性TGF-β1抑制BMNK细胞mTORC1活性、线粒体氧化磷酸化、增殖和细胞毒性;临床阶段TGF-β1通路抑制剂galunisertib预处理可恢复上述功能,阻断TGF-β1信号在白血病异种移植小鼠模型中改善NK细胞抗肿瘤活性。
要点
- allo-HSCT后早期复发AML患者BMNK细胞效应功能受损,与活性TGF-β1水平升高相关。
- CD4+ T细胞表面GARP过表达诱导TGF-β1活化,抑制BMNK细胞mTORC1、线粒体氧化磷酸化和细胞毒性。
- galunisertib预处理可恢复BMNK细胞mTORC1活性、线粒体稳态和细胞毒性;阻断TGF-β1信号改善小鼠模型NK细胞抗肿瘤活性。
核心结论
- 研究揭示allo-HSCT后早期复发AML患者BMNK细胞功能障碍机制,并提示靶向抑制TGF-β1信号可能改善allo-HSCT或NK细胞免疫治疗患者的结局。
研究设计与样本
- 体外实验系统分析allo-HSCT后早期复发AML患者骨髓来源NK(BMNK)细胞功能障碍机制,并采用白血病异种移植小鼠模型验证。
主要发现
- allo-HSCT后早期复发AML患者中,较高水平活性TGF-β1与BMNK细胞效应功能受损相关。
- CD4+ T细胞表面GARP过表达诱导TGF-β1活化。
- 活性TGF-β1显著抑制BMNK细胞mTORC1活性、线粒体氧化磷酸化、增殖和细胞毒性。
- galunisertib预处理显著恢复BMNK细胞mTORC1活性、线粒体稳态和细胞毒性。
- 阻断TGF-β1信号在白血病异种移植小鼠模型中改善NK细胞抗肿瘤活性。
临床怎么用
- 作者认为靶向抑制TGF-β1信号可能代表一种潜在治疗干预,以改善接受allo-HSCT或NK细胞免疫治疗AML患者的结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Relapse is a leading cause of death after allogeneic hematopoietic stem cell transplantation (allo-HSCT) for acute myeloid leukemia (AML). However, the underlying mechanisms remain poorly understood. Natural killer (NK) cells play a crucial role in tumor surveillance and cancer immunotherapy, and NK cell dysfunction has been observed in various tumors. Here, we performed ex vivo experiments to systematically characterize the mechanisms underlying the dysfunction of bone marrow-derived NK (BMNK) cells isolated from AML patients experiencing early relapse after allo-HSCT. We demonstrated that higher levels of active transforming growth factor β1 (TGF-β1) were associated with impaired effector function of BMNK cells in these AML patients. TGF-β1 activation was induced by the overexpression of glycoprotein A repetitions predominant on the surface of CD4+ T cells. Active TGF-β1 significantly suppressed mTORC1 activity, mitochondrial oxidative phosphorylation, the proliferation, and cytotoxicity of BMNK cells. Furthermore, pretreatment with the clinical stage TGF-β1 pathway inhibitor, galunisertib, significantly restored mTORC1 activity, mitochondrial homeostasis, and cytotoxicity. Importantly, the blockade of the TGF-β1 signaling improved the antitumor activity of NK cells in a leukemia xenograft mouse model. Thus, our findings reveal a mechanism explaining BMNK cell dysfunction and suggest that targeted inhibition of TGF-β1 signaling may represent a potential therapeutic intervention to improve outcomes in AML patients undergoing allo-HSCT or NK cell-based immunotherapy.
引用
- Wang D, Sun Z, Zhu X, et al. GARP-mediated active TGF-β1 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT. Blood. 2022. PMID: 35981475. doi:10.1182/blood.2022015474
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。